3SBio (HK:1530) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
3SBio’s subsidiary, Shenyang Sunshine, has entered into a strategic agreement with Haihe Biopharma to exclusively commercialize Paclitaxel Oral Solution in Mainland China and Hong Kong. This collaboration involves Shenyang Sunshine making initial and milestone payments to RMX Biopharma, which will continue overseeing clinical trials and development. Investors are advised to remain cautious as the product’s successful commercialization is not guaranteed.
For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money